...
首页> 外文期刊>Journal of cataract and refractive surgery >Evaluation of the prophylactic use of mitomycin-C to inhibit haze formation after photorefractive keratectomy.
【24h】

Evaluation of the prophylactic use of mitomycin-C to inhibit haze formation after photorefractive keratectomy.

机译:丝裂霉素C预防光折射性角膜切除术后雾霾形成的预防性使用的评估。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To evaluate the results of the prophylactic use of mitomycin-C to inhibit haze formation after excimer laser photorefractive keratectomy (PRK) for medium and high myopia in eyes that were not good candidates for laser in situ keratomileusis (LASIK). SETTING: Carones Ophthalmology Center, Milan, Italy. METHODS: This prospective randomized masked study comprised 60 consecutive eyes (60 patients). The inclusion criteria were a spherical equivalent correction between -6.00 and -10.00 diopters (D) and inadequate corneal thickness to allow a LASIK procedure with a residual stromal thickness of more than 250 microm. The eyes were divided into 2 groups according to the randomization protocol. After PRK, the study group eyes were treated with a single intraoperative dose of mitomycin-C (0.2 mg/mL), applied topically with a soaked microsponge placed over the ablated area and maintained for 2 minutes. The control eyes did not receive this treatment. Refraction, uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), and slitlamp evidence of corneal opacity (haze) or other visible complications were evaluated. RESULTS: No toxic or side effects were encountered postoperatively. No study group eye had a haze rate higher than 1 during the 6-month follow-up; 19 eyes (63%) in the control group did (P =.01). At 6 months, the between-group difference in the refractive outcome was statistically significant (P =.05), with 26 study group eyes (87%) and 14 control eyes (47%) within +/-0.50 D of the attempted correction. No study group eye had a BCVA loss during the follow-up; 7 control eyes had lost 1 to 3 lines at 6 months (P =.0006). CONCLUSIONS: The prophylactic use of a diluted mitomycin-C 0.02% solution applied intraoperatively in a single dose after PRK produced lower haze rates, better UCVA and BCVA results, and more accurate refractive outcomes than those achieved in the control group.
机译:目的:评估在不适合进行激光原位角膜磨镶术(LASIK)的中,高度近视准分子激光屈光性角膜切除术(PRK)后预防性使用丝裂霉素C抑制雾霾形成的结果。地点:意大利米兰Carones眼科中心。方法:这项前瞻性随机掩盖研究包括60只连续的眼睛(60例患者)。纳入标准为-6.00至-10.00屈光度(D)之间的球面等效矫正,并且角膜厚度不足以允许进行LASIK手术,残余基质厚度大于250微米。根据随机方案将眼睛分为两组。 PRK手术后,研究组的眼睛接受单次术中丝裂霉素C(0.2 mg / mL)的治疗,将局部浸透的微海绵浸泡在消融区域,并保持2分钟。对照眼睛没有接受这种治疗。评估了屈光度,未矫正视力(UCVA),最佳矫正视力(BCVA)和角膜混浊(雾状)或其他可见并发症的裂隙灯证据。结果:术后未见任何毒性或副作用。在6个月的随访中,没有研究组的眼睛雾度高于1。对照组有19只眼(63%)(P = .01)。在6个月时,屈光结局的组间差异具有统计学意义(P = .05),其中26只研究组眼(87%)和14只对照眼(47%)在尝试校正的+/- 0.50 D之内。在随访期间,没有研究组的眼睛有BCVA损失。 7只对照眼在6个月时损失了1至3条线(P = .0006)。结论:与对照组相比,在PRK手术后单次手术中预防性使用稀释的丝裂霉素C 0.02%溶液可产生更低的雾度,更好的UCVA和BCVA结果以及更准确的屈光结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号